Instil Bio Stock Today

TIL Stock  USD 8.55  0.41  4.58%   

Performance

Weakest

 
Weak
 
Strong

Odds Of Distress

Risky

 
High
 
Low
Instil Bio is selling for 8.55 as of the 26th of February 2026. This is a 4.58% down since the beginning of the trading day. The stock's lowest day price was 8.53. Instil Bio has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 28th of November 2025 and ending today, the 26th of February 2026. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
19th of March 2021
Category
Healthcare
Classification
Health Care
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company was incorporated in 2018 and is headquartered in Dallas, Texas. Instil Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 6.78 M outstanding shares of which 462.75 K shares are at this time shorted by investors with about 1.84 days to cover. More on Instil Bio

Moving against Instil Stock

  0.81GXEA Galapagos NVPairCorr
  0.778VP1 AVRICORE HEALTH INCPairCorr
  0.6VALN Valneva SE ADRPairCorr
  0.51DNTH Dianthus TherapeuticsPairCorr
  0.48DNLI Denali Therapeutics Earnings Call This WeekPairCorr
  0.362CG NANOSPHERE HEASCIENCESPairCorr

Instil Stock Highlights

ESG Sustainability
Environmental
Governance
Social
Old Names[Till Capital Ltd, TIPTEL, Trilogy International Limited]
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover3.0E-44.0E-4
Fairly Down
Slightly volatile
Total Current Liabilities8.6 M9.1 M
Notably Down
Slightly volatile
Total Assets368.5 M303.1 M
Fairly Up
Slightly volatile
Total Current Assets233.6 M143.1 M
Way Up
Slightly volatile
Debt Levels
By employing borrowed capital, Instil Bio can potentially magnify investment returns. Examining the debt-to-assets ratio offers investors perspective on Instil Bio's use of financial leverage and reveals what portion of Instil Bio's asset base relies on creditor financing.
Liquidity
Instil Bio has 86.89 M in debt with debt to equity (D/E) ratio of 0.12, which may show that the company is not taking advantage of profits from borrowing. Instil Bio has a current ratio of 8.34, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Instil to invest in growth at high rates of return.

Begin Period Cash Flow

9.15 Million
Instil Bio (TIL) is traded on NASDAQ Exchange in USA and employs 14 people. Instil Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a total capitalization of 60.77 M. Instil Bio runs under Biotechnology sector within Health Care industry. The entity has 6.78 M outstanding shares of which 462.75 K shares are at this time shorted by investors with about 1.84 days to cover. Instil Bio has about 354.61 M in cash with (55.7 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.73.
Check Instil Bio Probability Of Bankruptcy
Ownership Allocation
The market capitalization of Instil Bio is $60.77 Million. Over half of Instil Bio's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Instil Ownership Details

Instil Stock Institutional Holders

InstituionRecorded OnShares
Boxer Capital Management, Llc2025-06-30
70.7 K
Renaissance Technologies Corp2025-06-30
70.7 K
Northern Trust Corp2025-06-30
64.4 K
Assenagon Asset Management Sa2025-06-30
57.5 K
Blackrock Inc2025-06-30
50.7 K
Macquarie Group Ltd2025-06-30
50 K
Geode Capital Management, Llc2025-06-30
43.1 K
State Street Corp2025-06-30
17.6 K
Trexquant Investment Lp2025-06-30
17.4 K
Bml Capital Management Llc2025-06-30
534.9 K
Cpmg Inc2025-06-30
410.9 K
View Instil Bio Diagnostics

Instil Bio Historical Income Statement

At this time, Instil Bio's Interest Income is quite stable compared to the past year. Interest Expense is expected to rise to about 10.9 M this year, although the value of Net Interest Income is projected to rise to (2.2 M). View More Fundamentals

Instil Stock Against Markets

Instil Bio Corporate Management

Sandeep MDCFO OfficerProfile
Timothy MooreChief OfficerProfile
Bronson CrouchChairman CEOProfile
Sumita JDCompliance, LegalProfile
James MDChief OfficerProfile
Mark DudleyChief OfficerProfile
Robert MBBSHead DevelopmentProfile
When determining whether Instil Bio is a strong investment it is important to analyze Instil Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Instil Bio's future performance. For an informed investment choice regarding Instil Stock, refer to the following important reports:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Instil Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Instil Stock please use our How to buy in Instil Stock guide.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Instil Bio. If investors know Instil will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Instil Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(11.35)
Return On Assets
(0.15)
Return On Equity
(0.51)
Instil Bio's market price often diverges from its book value, the accounting figure shown on Instil's balance sheet. Smart investors calculate Instil Bio's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Instil Bio's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Instil Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Instil Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Instil Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.